Source:http://linkedlifedata.com/resource/pubmed/id/19581763
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2009-7-7
|
pubmed:commentsCorrections | |
pubmed:language |
kor
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1738-222X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
119-21
|
pubmed:meshHeading |
pubmed-meshheading:19581763-Antiviral Agents,
pubmed-meshheading:19581763-Arabinofuranosyluracil,
pubmed-meshheading:19581763-Drug Resistance, Viral,
pubmed-meshheading:19581763-Hepatitis B, Chronic,
pubmed-meshheading:19581763-Humans,
pubmed-meshheading:19581763-Lamivudine,
pubmed-meshheading:19581763-Practice Guidelines as Topic
|
pubmed:year |
2009
|
pubmed:articleTitle |
[Clevudine therapy in patients with chronic hepatitis B].
|
pubmed:publicationType |
Editorial,
Comment
|